Hikma Pharmaceuticals announces the launch of Hikma 503B – a new outsourced sterile compounding business focused on providing high quality, ready-to-administer injectable medications that are customized to the specific needs of patients in the United States.
10 January 2022
Case Study, Corporate
For more information visit https://www.hikma503b.com/
Related news
Hikma launches Icosapent Ethyl Capsules, 0.5g, in the US
21 March 2023
Hikma launches Cefazolin for Injection, USP, in the US
20 March 2023